PointState Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

PointState Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-304,600	Closed	-$11.5M	–	155
2017 Q3	$11.5M	Buy	+304,600	New	+$9.91M	0.1%	102
2016 Q2	–	Sell	-150,000	Closed	-$4.19M	–	110
2016 Q1	$4.19M	Sell	150,000 -300,000	-67%	-$6.54M	0.11%	63
2015 Q4	$16M	Buy	+450,000	New	+$15.9M	0.41%	40
2015 Q2	–	Sell	-250,000	Closed	-$8.15M	–	149
2015 Q1	$8.15M	Buy	+250,000	New	+$8.59M	0.11%	85

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

PointState Capital's ACAD Position: Q4 2017 in Review

PointState Capital sold out of Acadia Pharmaceuticals (ACAD) in Q4 2017, closing a stake of 304,600 shares — an estimated $11.5M sold.

PointState Capital first reported a position in ACAD in Q1 2015 and held it in 4 quarters. The position peaked at $16M in Q4 2015. 210 funds tracked by Wall St. Rank hold ACAD as of Q4 2017.

PointState Capital reported no remaining Acadia Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
PointState Capital sold 304,600 Acadia Pharmaceuticals shares in Q4 2017, an estimated $11.5M.
PointState Capital first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 4 quarters.
PointState Capital's Acadia Pharmaceuticals position peaked at $16M in Q4 2015.
210 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2017.

Based on PointState Capital's 13F filing for Q4 2017, filed 14 Feb 2018.